Last edition
News about "monotherapy"
Eli Lilly Reports Biomarker Changes With Taltz-Zepbound Combination
Eli Lilly has reported broader immune, inflammatory and metabolic biomarker changes with Taltz and Zepbound compared with Taltz alone in the TOGETHER-PsO trial.
Monotherapy | 12/10/2026 | By News Bureau | 168
US FDA Grants Breakthrough Therapy Designation to Lilly's Olomorasib for Advanced Pancreatic Cancer
The US FDA has granted Breakthrough Therapy designation to Eli Lilly's investigational KRAS G12C inhibitor, olomorasib, for treating previously treated advanced pancreatic cancer, reinforcing its potential across difficult-to-treat KRAS-driven cancers.
Monotherapy | 04/08/2026 | By News Bureau | 104
Lupin and Zydus Partner to Co-Market Semaglutide Injection in India
Lupin has secured semi-exclusive rights to co-market Zydus’ Semaglutide injection in India under the brands Semanext and Livarise, while Zydus will continue marketing it under the brand names SEMAGLYNTM, MASHEMATM and ALTERMETM.
Monotherapy | 18/03/2026 | By News Bureau | 463
IDEAYA Biosciences Enrols First Patient in Phase I Trial of IDE034 Bispecific TOP1 ADC
Precision oncology firm IDEAYA begins Phase I evaluation of IDE034, a PTK7/B7H3 bispecific TOP1 ADC, advancing its ADC and DNA damage response combination strategy in solid tumours.
Monotherapy | 02/03/2026 | By News Bureau | 305
CStone Pharmaceuticals Secures UK MHRA Approval for Sugemalimab in Stage III NSCLC
The UK Medicines and Healthcare products Regulatory Agency grants a new indication for sugemalimab monotherapy in unresectable Stage III NSCLC, expanding its European footprint and global commercial reach.
Monotherapy | 23/02/2026 | By News Bureau | 298
Pin Therapeutics Administers First Dose of PIN-5018 in Adenoid Cystic Carcinoma Patient
Pin Therapeutics, a clinical-stage biotechnology company focused on targeted protein degradation, has begun dosing in a Phase 1 clinical trial evaluating its CK1α-selective degrader, PIN-5018. The first patient enrolled in the study has adenoid cystic carcinoma (ACC), a rare malignancy with limited treatment options.
Monotherapy | 24/11/2025 | By Dineshwori | 389
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy